Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Chia, Stephen"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-18 z 18
    Tytuł:
    Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in Canada.
    Autorzy:
    Jackson EB; BC Cancer Vancouver, Vancouver, BC V5Z 4E6, Canada.; Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
    Simmons CE; BC Cancer Vancouver, Vancouver, BC V5Z 4E6, Canada.; Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
    Chia SK; BC Cancer Vancouver, Vancouver, BC V5Z 4E6, Canada.; Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
    Pokaż więcej
    Źródło:
    Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Aug 01; Vol. 30 (8), pp. 7263-7274. Date of Electronic Publication: 2023 Aug 01.
    Typ publikacji:
    Review; Journal Article
    MeSH Terms:
    Breast Neoplasms*/therapy
    Humans ; Female ; Canada ; Geography
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895".
    Autorzy:
    Rayson D; Division of Medical Oncology, Department of Medicine, Queen Elizabeth II Health Sciences Center, Halifax, NS B3H 2Y9, Canada.
    Gandhi S; Division of Medical Oncology/Hematology, Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
    Joy AA; Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada.
    Brezden-Masley C; Division of Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
    Gelmon KA; Division of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada.
    Sehdev S; Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
    Cescon D; Department of Medical Oncology, University Health Network, Toronto, ON M5G 1Z5, Canada.
    Chia S; Division of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada.
    Pokaż więcej
    Źródło:
    Current oncology (Toronto, Ont.) [Curr Oncol] 2023 May 16; Vol. 30 (5), pp. 5050-5053. Date of Electronic Publication: 2023 May 16.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Breast Neoplasms*/drug therapy
    Humans ; Female ; Trastuzumab ; Neoadjuvant Therapy ; Advisory Committees ; Receptor, ErbB-2 ; Canada
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.
    Autorzy:
    Rayson D; Division of Medical Oncology, Department of Medicine, Queen Elizabeth II Health Sciences Center, Halifax, NS B3H 2Y9, Canada.
    Gandhi S; Division of Medical Oncology/Hematology, Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, ON M5M 3J1, Canada.
    Joy AA; Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada.
    Brezden-Masley C; Division of Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
    Gelmon KA; Division of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada.
    Sehdev S; Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
    Cescon D; Department of Medical Oncology, University Health Network, Toronto, ON M5G 1Z5, Canada.
    Chia S; Division of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada.
    Pokaż więcej
    Źródło:
    Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Dec 16; Vol. 29 (12), pp. 9891-9895. Date of Electronic Publication: 2022 Dec 16.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Breast Neoplasms*/pathology
    Humans ; Female ; Neoadjuvant Therapy/methods ; Receptor, ErbB-2 ; Canada ; Trastuzumab/therapeutic use
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer.
    Autorzy:
    Pauls M; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada.
    Chia S; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada.
    Pokaż więcej
    Źródło:
    Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Jul 20; Vol. 29 (7), pp. 5139-5149. Date of Electronic Publication: 2022 Jul 20.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Breast Neoplasms*/pathology
    Chemotherapy, Adjuvant ; Female ; Gene Expression Profiling ; Genomics ; Humans ; Neoplasm Recurrence, Local/drug therapy
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
    Autorzy:
    Lambert LK; School of Nursing, University of British Columbia, Vancouver, BC V6T 2B5, Canada.; BC Cancer, Vancouver, BC V5Z 4E6, Canada.
    Balneaves LG; College of Nursing, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
    Howard AF; School of Nursing, University of British Columbia, Vancouver, BC V6T 2B5, Canada.
    Chia SLK; BC Cancer, Vancouver, BC V5Z 4E6, Canada.
    Gotay CC; School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
    Pokaż więcej
    Źródło:
    Current oncology (Toronto, Ont.) [Curr Oncol] 2021 Apr 09; Vol. 28 (2), pp. 1472-1482. Date of Electronic Publication: 2021 Apr 09.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Breast Neoplasms*/drug therapy
    Cancer Survivors*
    Chemotherapy, Adjuvant ; Female ; Health Personnel ; Humans ; Neoplasm Recurrence, Local
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Prophylactic Surgery in the BRCA+ Patient: Do Women Develop Breast Cancer While Waiting?
    Autorzy:
    Macadam SA; Division of Plastic & Reconstructive Surgery, Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
    Slater K; Division of Plastic & Reconstructive Surgery, Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
    Cheifetz RE; Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
    Jansen L; Division of Plastic & Reconstructive Surgery, Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
    Chia S; Department of Medical Oncology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
    Brasher PMA; Center for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, BC V5Z 1M9, Canada.
    Bovill ES; Division of Plastic & Reconstructive Surgery, Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
    Pokaż więcej
    Źródło:
    Current oncology (Toronto, Ont.) [Curr Oncol] 2021 Jan 25; Vol. 28 (1), pp. 702-715. Date of Electronic Publication: 2021 Jan 25.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Breast Neoplasms*/epidemiology
    Breast Neoplasms*/genetics
    Breast Neoplasms*/prevention & control
    Mammaplasty*
    Prophylactic Mastectomy*
    Cohort Studies ; Female ; Humans ; Mastectomy
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    Autorzy:
    Lambert LK; School of Nursing, University of British Columbia, T201-2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada.
    Balneaves LG; College of Nursing, Rady Faculty of Health Sciences, University of Manitoba, 89 Curry Place, Helen Glass Centre for Nursing, Winnipeg, MB, R3T 2N2, Canada. .
    Howard AF; School of Nursing, University of British Columbia, T201-2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada.
    Chia SK; British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, V5Z 4E6, Canada.
    Gotay CC; School of Population and Public Health, University of British Columbia, V2206 East Mall, Vancouver, BC, V6T 1Z3, Canada.
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2018 Jul 11; Vol. 18 (1), pp. 732. Date of Electronic Publication: 2018 Jul 11.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Cancer Survivors*
    Aromatase Inhibitors/*therapeutic use
    Breast Neoplasms/*drug therapy
    Tamoxifen/*therapeutic use
    Aged ; Breast Neoplasms/mortality ; Breast Neoplasms/psychology ; Combined Modality Therapy ; Female ; Health Personnel ; Humans ; Middle Aged ; Quality of Life ; Social Support
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.
    Autorzy:
    Asleh-Aburaya K; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.
    Sheffield BS; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.
    Kos Z; Department of Pathology and Laboratory Medicine, University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada.
    Won JR; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, Canadian Immunohistochemistry Quality Control (CIQC), University of British Columbia, Vancouver, BC, Canada.
    Wang XQ; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.
    Gao D; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.
    Wolber R; Department of Pathology and Laboratory Medicine, Lions Gate Hospital, North Vancouver, BC, Canada.
    Gilks CB; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, Canadian Immunohistochemistry Quality Control (CIQC), University of British Columbia, Vancouver, BC, Canada.
    Bernard PS; Department of Pathology, University of Utah/Health Sciences, Salt Lake City, UT, USA.
    Chia SK; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
    Nielsen TO; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.
    Pokaż więcej
    Źródło:
    Histopathology [Histopathology] 2017 Jan; Vol. 70 (2), pp. 185-194. Date of Electronic Publication: 2016 Sep 29.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Biomarkers, Tumor/*analysis
    Breast Neoplasms/*classification
    Carcinoma, Ductal, Breast/*classification
    Nestin/*biosynthesis
    Phosphoric Monoester Hydrolases/*biosynthesis
    Adult ; Aged ; Breast Neoplasms/mortality ; Carcinoma, Ductal, Breast/mortality ; Female ; Gene Expression Profiling/methods ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Middle Aged ; Nestin/analysis ; Phosphoric Monoester Hydrolases/analysis ; Prognosis ; Proportional Hazards Models ; Receptors, Estrogen/biosynthesis ; Tissue Array Analysis ; Transcriptome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.
    Autorzy:
    Eirew P; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Steif A; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Khattra J; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Ha G; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Yap D; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Farahani H; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Gelmon K; Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada.
    Chia S; Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada.
    Mar C; Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada.
    Wan A; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.
    Laks E; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Biele J; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Shumansky K; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.
    Rosner J; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.
    McPherson A; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Nielsen C; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Roth AJ; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Lefebvre C; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Bashashati A; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    de Souza C; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.
    Siu C; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.
    Aniba R; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Brimhall J; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.
    Oloumi A; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Osako T; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Bruna A; 1] Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK [2] Cancer Research UK Cambridge Research Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
    Sandoval JL; 1] Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK [2] Cancer Research UK Cambridge Research Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
    Algara T; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
    Greenwood W; 1] Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK [2] Cancer Research UK Cambridge Research Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
    Leung K; 1] Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada [2] Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada.
    Cheng H; 1] Department of Experimental Therapeutics, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada.
    Xue H; 1] Department of Experimental Therapeutics, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada.
    Wang Y; 1] Department of Experimental Therapeutics, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada.
    Lin D; 1] Department of Experimental Therapeutics, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada.
    Mungall AJ; Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada.
    Moore R; Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada.
    Zhao Y; Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada.
    Lorette J; Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada.
    Nguyen L; 1] Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada [2] Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada.
    Huntsman D; 1] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [2] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada.
    Eaves CJ; 1] Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada [2] Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada.
    Hansen C; 1] Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada [2] Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada.
    Marra MA; Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada.
    Caldas C; 1] Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK [2] Cancer Research UK Cambridge Research Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
    Shah SP; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada.
    Aparicio S; 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada [4] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada.
    Pokaż więcej
    Źródło:
    Nature [Nature] 2015 Feb 19; Vol. 518 (7539), pp. 422-6. Date of Electronic Publication: 2014 Nov 26.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Single-Cell Analysis*
    Xenograft Model Antitumor Assays*/methods
    Breast Neoplasms/*genetics
    Breast Neoplasms/*pathology
    Clone Cells/*metabolism
    Clone Cells/*pathology
    Genome, Human/*genetics
    Animals ; Breast Neoplasms/secondary ; DNA Mutational Analysis ; Genomics ; Genotype ; High-Throughput Nucleotide Sequencing ; Humans ; Mice ; Neoplasm Transplantation ; Time Factors ; Transplantation, Heterologous
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
    Autorzy:
    Teckle P; Canadian Centre for Applied Research in Cancer Control, British Columbia Cancer Agency, Vancouver, BC, Canada. .
    McTaggart-Cowan H
    Van der Hoek K
    Chia S
    Melosky B
    Gelmon K
    Peacock S
    Pokaż więcej
    Źródło:
    Health and quality of life outcomes [Health Qual Life Outcomes] 2013 Dec 01; Vol. 11, pp. 203. Date of Electronic Publication: 2013 Dec 01.
    Typ publikacji:
    Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Validation Study
    MeSH Terms:
    Patient Preference*
    Breast Neoplasms/*psychology
    Colorectal Neoplasms/*psychology
    Lung Neoplasms/*psychology
    Quality of Life/*psychology
    Surveys and Questionnaires/*standards
    Adult ; Aged ; British Columbia ; Female ; Humans ; Linear Models ; Male ; Quality-Adjusted Life Years
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
    Autorzy:
    Pataky R; Cancer Control Research, BC Cancer Agency, 675 W, 10th Ave, Vancouver, BC V5Z 1L3, Canada.
    Armstrong L
    Chia S
    Coldman AJ
    Kim-Sing C
    McGillivray B
    Scott J
    Wilson CM
    Peacock S
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2013 Jul 10; Vol. 13, pp. 339. Date of Electronic Publication: 2013 Jul 10.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Genes, BRCA1*
    Genes, BRCA2*
    Mutation*
    Breast Neoplasms/*economics
    Early Detection of Cancer/*economics
    Early Detection of Cancer/*methods
    Magnetic Resonance Imaging/*economics
    Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Canada ; Cost-Benefit Analysis ; Humans ; Mammography/economics ; Markov Chains ; Quality-Adjusted Life Years
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
    Autorzy:
    Shah SP; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada. />Roth A
    Goya R
    Oloumi A
    Ha G
    Zhao Y
    Turashvili G
    Ding J
    Tse K
    Haffari G
    Bashashati A
    Prentice LM
    Khattra J
    Burleigh A
    Yap D
    Bernard V
    McPherson A
    Shumansky K
    Crisan A
    Giuliany R
    Heravi-Moussavi A
    Rosner J
    Lai D
    Birol I
    Varhol R
    Tam A
    Dhalla N
    Zeng T
    Ma K
    Chan SK
    Griffith M
    Moradian A
    Cheng SW
    Morin GB
    Watson P
    Gelmon K
    Chia S
    Chin SF
    Curtis C
    Rueda OM
    Pharoah PD
    Damaraju S
    Mackey J
    Hoon K
    Harkins T
    Tadigotla V
    Sigaroudinia M
    Gascard P
    Tlsty T
    Costello JF
    Meyer IM
    Eaves CJ
    Wasserman WW
    Jones S
    Huntsman D
    Hirst M
    Caldas C
    Marra MA
    Aparicio S
    Pokaż więcej
    Źródło:
    Nature [Nature] 2012 Apr 04; Vol. 486 (7403), pp. 395-9. Date of Electronic Publication: 2012 Apr 04.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    Evolution, Molecular*
    Breast Neoplasms/*genetics
    Breast Neoplasms/*pathology
    Mutation/*genetics
    Alleles ; Breast Neoplasms/diagnosis ; Clone Cells/metabolism ; Clone Cells/pathology ; DNA Copy Number Variations/genetics ; DNA Mutational Analysis ; Disease Progression ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic/genetics ; Genotype ; High-Throughput Nucleotide Sequencing ; Humans ; INDEL Mutation/genetics ; Point Mutation/genetics ; Precision Medicine ; Reproducibility of Results ; Sequence Analysis, RNA
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities.
    Autorzy:
    Teckle P; Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada. />Peacock S
    McTaggart-Cowan H
    van der Hoek K
    Chia S
    Melosky B
    Gelmon K
    Pokaż więcej
    Źródło:
    Health and quality of life outcomes [Health Qual Life Outcomes] 2011 Nov 28; Vol. 9, pp. 106. Date of Electronic Publication: 2011 Nov 28.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Validation Study
    MeSH Terms:
    Severity of Illness Index*
    Breast Neoplasms/*pathology
    Colorectal Neoplasms/*pathology
    Lung Neoplasms/*pathology
    Psychometrics/*instrumentation
    Analysis of Variance ; Female ; Humans ; Male ; Middle Aged ; Quality of Life ; Self Disclosure ; Statistics, Nonparametric ; Surveys and Questionnaires
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
    Autorzy:
    Prentice LM; Department of Pathology and Prostate Centre, Genetic Pathology Evaluation Centre, Vancouver General Hospital, Vancouver, BC, Canada V6H 3Z6.
    Shadeo A
    Lestou VS
    Miller MA
    deLeeuw RJ
    Makretsov N
    Turbin D
    Brown LA
    Macpherson N
    Yorida E
    Cheang MC
    Bentley J
    Chia S
    Nielsen TO
    Gilks CB
    Lam W
    Huntsman DG
    Pokaż więcej
    Źródło:
    Oncogene [Oncogene] 2005 Nov 10; Vol. 24 (49), pp. 7281-9.
    Typ publikacji:
    Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Gene Amplification*
    Gene Rearrangement*
    Breast Neoplasms/*genetics
    Neuregulin-1/*genetics
    Nuclear Proteins/*genetics
    Breast Neoplasms/metabolism ; Chromosomes, Artificial, Bacterial ; Chromosomes, Human, Pair 8/genetics ; DNA, Neoplasm/genetics ; DNA, Neoplasm/metabolism ; ErbB Receptors/metabolism ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; In Situ Hybridization, Fluorescence ; Microarray Analysis ; Neuregulin-1/metabolism ; Nuclear Proteins/metabolism ; Nucleic Acid Hybridization ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptor, ErbB-3/metabolism ; Receptor, ErbB-4 ; Survival Rate ; Zinc Fingers
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-18 z 18

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies